HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir AB (STO:MVIRB)(OMX: MVIR), a research-based speciality pharmaceutical company focused on infectious diseases, reports the following key news concerning their hepatitis C projects.
Medivir programmes in collaboration with Tibotec Pharmaceuticals Medivir and Tibotec Pharmaceuticals have two programmes for the development of antiviral therapies for future treatment of hepatitis C (HCV), these are based on the HCV protease and polymerase drug targets.
Medivir AB (STO:MVIRB)(OMX: MVIR), a research-based speciality pharmaceutical company focused on infectious diseases, reports the following key news concerning their hepatitis C projects.
Medivir programmes in collaboration with Tibotec Pharmaceuticals Medivir and Tibotec Pharmaceuticals have two programmes for the development of antiviral therapies for future treatment of hepatitis C (HCV), these are based on the HCV protease and polymerase drug targets.
